From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

ValiRx – petty cash placing to keep the lights on. How many Brokers does this £0.9m company need?

By Nigel Somerville, the Deputy Sheriff of AIM | Tuesday 7 January 2020


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


When I first commented on AIM-listed cancer drug developer ValiRx (VAL) back in 2016 the shares had just seen a pump’n’dump which pushed the stock up to 21p before a placing at just 12p. Now the stock is just 0.1p and on a market cap of £0.9m (source: ADVFN): never mind the 90% club, this is a fully paid up member of the 99% club. And now we have a placing for just £200,000 gross…..and Broker number three joins the fray, although as Tom Winnifrith points out the RNS will have to be reissued. How on earth can you justify paying three broker retainers for a company worth less than a million pounds?

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

CTAI

Catenai – monster dilution

Time left: 05:39:18